Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732703 · ClinicalTrials.gov registry record · Phase 1
Myeloma-Developing Regimens Using Genomics (MyDRUG)
A Phase 1 study of Relapsed Refractory Multiple Myeloma, sponsored by Multiple Myeloma Research Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 16
- Study locations
NCT03732703 is a Phase 1 study of Relapsed Refractory Multiple Myeloma that has completed, run by Multiple Myeloma Research Consortium. The registered enrollment target is 103 participants, below the 173-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (40% lower). The trial reports 16 study locations across 12 states.
The verdict
NCT03732703, a Phase 1 study of Relapsed Refractory Multiple Myeloma, has completed, sponsored by Multiple Myeloma Research Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 16
- Study locations
Study Summary
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).
Conditions Studied
Interventions
- DRUG Abemaciclib, dexamethasone, ixazomib, pomalidomide
- DRUG Enasidenib, dexamethasone, ixazomib, pomalidomide
- DRUG Cobimetinib, dexamethasone, ixazomib, pomalidomide
- DRUG Erdafitinib, dexamethasone, ixazomib, pomalidomide
- DRUG Venetoclax, dexamethasone, ixazomib, pomalidomide
Study Locations (16)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Health System - Ann Arbor
- Karmanos Cancer Center - Detroit
New York
- Mount Sinai School of Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic - Arizona - Phoenix
California
- City of Hope - Duarte
Georgia
- Emory University - Atlanta
Minnesota
- Mayo Clinic - Minnesota - Rochester
Missouri
- Washington University School of Medicine Division of Medical Oncology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732703
The ClinicalTrials.gov registry entry for NCT03732703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (40% lower). The listed sponsor is Multiple Myeloma Research Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Abemaciclib, dexamethasone, ixazomib, pomalidomide is the first listed.
NCT03732703 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT03732703 about?
NCT03732703 is a clinical study titled "Myeloma-Developing Regimens Using Genomics (MyDRUG)". The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; ...
What is the current status of trial NCT03732703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2019-04-01. Estimated completion is 2024-12-31.
What conditions does trial NCT03732703 study?
This clinical trial studies the following conditions: Relapsed Refractory Multiple Myeloma.
What interventions are being tested in trial NCT03732703?
The interventions under investigation include: Abemaciclib, dexamethasone, ixazomib, pomalidomide (DRUG), Enasidenib, dexamethasone, ixazomib, pomalidomide (DRUG), Cobimetinib, dexamethasone, ixazomib, pomalidomide (DRUG), Erdafitinib, dexamethasone, ixazomib, pomalidomide (DRUG), Venetoclax, dexamethasone, ixazomib, pomalidomide (DRUG).
Who is sponsoring clinical trial NCT03732703?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03732703 being conducted?
This trial has 16 study locations across Arizona, California, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
-
ELISA in Relapsed/Refractory MM
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.